Controlling drug release from non-aqueous environments: Moderating delivery from ocular silicone oil drug reservoirs to combat proliferative vitreoretinopathy  by Cauldbeck, Helen et al.
Journal of Controlled Release 244 (2016) 41–51
Contents lists available at ScienceDirect
Journal of Controlled Release
j ourna l homepage: www.e lsev ie r .com/ locate / jconre lControlling drug release from non-aqueous environments: Moderating
delivery from ocular silicone oil drug reservoirs to combat
proliferative vitreoretinopathyHelen Cauldbeck a, Maude Le Hellaye a,b, Mark Long c, Stephnie M. Kennedy b, Rachel L. Williams b,
Victoria R. Kearns b,⁎, Steve P. Rannard a,⁎
a Department of Chemistry, University of Liverpool, Crown Street, L69 7ZD, UK
b Department of Eye and Vision Science, University of Liverpool, Liverpool, UK
c Unilever Research Centre, Port Sunlight, Quarry Road East, Bebington, Wirral CH63 3JW, UK⁎ Corresponding authors.
E-mail addresses: vkearns@liverpool.ac.uk (V.R. Kearn
(S.P. Rannard).
http://dx.doi.org/10.1016/j.jconrel.2016.11.010
0168-3659/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 24 August 2016
Received in revised form 5 November 2016
Accepted 10 November 2016
Available online 12 November 2016In a number of cases of retinal detachment, treatmentmay require the removal of the vitreous humourwithin the
eye and replacement with silicone oil to aid healing of the retina. The insertion of silicone oil offers the opportu-
nity to also deliver drugs to the inside of the eye; however, drug solubility in silicone oil is poor and release from
this hydrophobic drug reservoir is not readily controlled. Here,wehave designed a range of statistical graft copol-
ymers that incorporate dimethylsiloxane and ethylene glycol repeat units within the side chains, allowing short
chains of oligo(ethylene glycol) to be solubilised within silicone oil and provide hydrogen bond acceptor sites to
interact with acid functional drug molecules. Our hypothesis included the potential for such interactions to be
able to delay/control drug release and for polymer architecture and composition to play a role in the silicone
oil miscibility of the targeted polymers. This strategy has been successfully demonstrated using both ibuprofen
and all-trans retinoic acid; drugs with anti-inﬂammatory and anti-proliferation activity. After the copolymers
were shown to be non-toxic to retinal pigment epithelial cells, studies of drug release using radiochemical ap-
proaches showed that the presence of 10 v/v% of a linear graft copolymer could extend ibuprofen release over
three-fold (from 3 days to N9 days)whilst the release of all-trans retinoic from the silicone oil phasewas extend-
ed to N72 days. These timescales are highly clinically relevant showing the potential to tune drug delivery during
the healing process and offer an efﬁcient means to improve patient outcomes.s), srannard@l
. This is an op© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Retinal detachment is a relatively common disorder requiring ur-
gent attention to prevent the potential for permanent reduction or
loss of sight [1]. The incidence of non-traumatic retinal detachment in
individualswith healthy eyesmay be as low as 5.4 cases/100,000 people
per year [2], but correlations with age, genetics [3], race, short-sight
(myopia) [4], previous surgical interventions (e.g. cataract surgery)
and underlying illness, such as diabetes, may increase this ﬁgure to
N50 cases/100,000 people per year [5,6]. The condition involves the
physical separation of the neuroretina from the supporting retinal pig-
ment epithelium (RPE) monolayer, a layer of hexagonally close packed
cells situated at the back of the human eye. Upon detachment, and sub-
sequent tearing, of the retina, aqueous from around the vitreous hu-
mour may accumulate between the two layers leading to furtheriverpool.ac.uk
en access article underseparation from the RPE; this is known as rhegmatogenous retinal de-
tachment. Retinal detachment may occur without the formation of a
tear either by the buildup of ﬂuid under the retina from blood vessels,
so called exudative retinal detachment, triggered by conditions such
as severe macular degeneration, very high blood pressure or certain
cancers such as choroidalmelanoma. Alternatively, tractional retinal de-
tachment may occur after scar tissue forms on the surface of the retina
and contracts, leading to separation of the retina from the RPE [7]; this
process is associated with proliferative diabetic retinopathy and prolif-
erative vitreoretinopathy (PVR). PVR is a known complication of
rhegmatogenous retinal detachment and recurring retinal detachment
as the formation of a tear in the retina results in the production of an in-
ﬂammatory microenvironment [8]. Several cell types are stimulated by
these cues, in particular RPE cells, which may proliferate and de-differ-
entiate into a macrophage-like phenotype. RPE cells may also undergo
epithelial-mesenchymal transition, probably as a result of exposure to
a variety of agents in the microenvironment such as members of the
transforming growth factor beta and platelet-derived growth factor
families [9]. The cells migrate towards the vitreous humour withthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cellular proteins, leading to the formation of new tissue. As this tissue
matures and is remodeled, it contracts, leading to the formation of a
scar. The epiretinal membrane of the scar continues to grow and later
contraction leads to further tension and additional retinal detachment
[10] with subsequent loss of vision [11].
Therapeutic intervention for retinal detachment includes the use of
pneumatic retinopexy, scleral buckle surgery and the combination of
vitrectomy/tamponade replacement. Pneumatic retinopexy requires
the injection of a gas bubble (air or perﬂuorocarbon) into the vitreous
cavity and careful positioning of the patients' head to align the bubble
with the detached area, this generates a light pressure which is able to
hold the tear against the RPE. The process takes up to three weeks, dur-
ingwhich the gas is slowly absorbed. It also leads to obvious restrictions
for the patient including postural and lifestyle limitations [12]. A scleral
buckle is a piece of silicone rubber or plastic that is sewn onto the exter-
nal surface of the eye to permanently deform the sclera towards the de-
tached retina [13]. The buckle may completely surround the eye if large
detachments are present [14].
A vitrectomy involves the removal of some or all of the vitreous hu-
mour from the eye and replacementwith a gas or silicone oil tamponade
[15]; a tamponade agent is a material that will plug or compress an area
or cavity. The hydrophobic nature of the tamponade inhibits the accu-
mulation of physiological liquids in the subretinal space, excludes in-
ﬂammatory factors and encourages reattachment. During the use of a
gas tamponade, the patient must lie predominantly facing downwards
for up to 4 weeks to ensure the gas bubble is aligned with the damaged
region and any remaining vitreous material is held away from the repair
site as themotion of the viscous ﬂuidmay lead to greater damage; again,
this is highly restricting to the patient. The use of a silicone oil tamponade
(Fig. 1)was reported almost 20 years ago to provide considerable patient
beneﬁts over the use of gaseous alternatives [16]. Silicone oil has manyFig. 1. Schematic cross-section of the a human eye showing A) the formation of a retinal
tear; and B) Replacement of the vitreous humour within the eye with a silicone oil
tamponade to aid healing of the tear whilst maintaining vision for the patient.beneﬁts for use as a tamponade agent including being chemically inert,
readily sterilized and optically clear, which allows at least some vision
in most patients [17]. It also allows considerably reduced postural re-
strictions and the ability to travel during the healing of the retina. Disad-
vantages include the need to remove the tamponade ultimately and
reported cases of elevated intraocular pressure.
Currently the action of the silicone oil tamponade is predominantly
physical and attempts to utilize the volume of injected oil as a drug de-
livery reservoir have been hampered by either the poor solubility of
many drugs within silicone oil or the inability to control release rates.
The opportunity has signiﬁcant clinical relevance as the ability to con-
trol the release of anti-proliferative drugs and/or anti-inﬂammatory
agents to the posterior of the eyewould present options to considerably
extend the therapeutic action of this surgical intervention [18]. Drug de-
livery from, and into, aqueous environments has been studied by nu-
merous research groups for many years and for many diseases [19],
including ocular conditions [20]. Much of the recent research has uti-
lized nanoparticle systems [21,22], supra-molecular assembly [23,24]
or polymer-drug conjugation [25,26], with highly efﬁcient targeting of
disease sites often reported using in vitro and in vivo animal models.
Many of these reports utilize either the poor water-solubility of the
drug compound or a cleavable chemistry to avoid instant/uncontrolled
drug release and mediate delivery to the target site. The challenges as-
sociated with the development of silicone oil tamponade drug delivery
reservoirs include: 1) the poor-solubility of drug compoundswithin sil-
icone oil, 2) the inherent low solubility of silicone-soluble drugs in
water, 3) a restricted range of silicone-soluble/miscible excipient mate-
rials to moderate release, and 4) difﬁculties in directly assessing drug
concentrations within the silicone oil phase. Polymer-drug conjugates
and nanoparticle delivery strategies have potential within this context,
however, the eye is considered as one of the most complex organs with
a series of unique barriers that limit ﬂuid transport, and hence drug de-
livery from conventional topical or systemic routes; the eye is isolated
by the blood-retinal and blood-aqueous barriers [27]. The presence of
residual nanoparticles, degradation products and cleaved polymer car-
riers leads to the potential for localized toxicity, especially with the con-
straints of clearance/transport from the posterior of the eye.
Herein we describe the design, synthesis and in vitro evaluation of a
new strategy for moderating drug delivery from silicone oil
tamponades. The approach involves the formation of silicone oil solu-
ble/miscibile polymeric excipients that are able to hydrogen bond to
acid functional drug compounds and alter release rates into aqueous en-
vironments. A series of studies using two clinically relevant drugs, and
mixtures with 3H-labelled drug compounds, clearly illustrates the clini-
cal potential for this novel approach.
2. Materials and methods
2.1. Materials
All-trans retinoic acid (atRA) was purchased from Xian Bosheng Bi-
ological Technology Co., Ltd. and used as received. Ibuprofen (Ibu) was
purchased from Tokyo Chemical Industry UK Ltd. and used as received.
Trimethylsiloxy terminated polydimethylsiloxane oil (silicone oil;
SiO1000; viscosity = 900–1200 cSt at 25 °C) was donated by Fluoron
GmbH and used as received. All deuterated solvents were purchased
from Sigma-Aldrich and used as received apart from CDCl3 where 0.1%
TMS was added. All solvents used were analytical grade and purchased
from Fisher. Resazurin was purchased from Sigma and used as received.
Alexa Fluor® 488 Phalloidin (Phalloidin) and 4′,6-diamidino-2-
phenylindole dihydrochloride (DAPI) were purchased from Invitrogen
and diluted in methanol or deionized water following the
manufacturer's instructions. Adult retinal pigment epithelial (ARPE-
19) cells were bought from American Type Culture Collection, Manas-
sas, VA, USA, catalogue number CRL 2302 and frozen stocks were stored
in-house. Dulbecco's Modiﬁed Eagle Medium/Ham's Nutrient Mixture
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Streptomycin 10 mg/mL streptomycin in 0.9% NaCl (Pen-Strep),
Amphotericin B solution 250 μg/mL in deionized water, Dulbecco's cal-
cium and magnesium free phosphate buffered saline (PBS), Trypsin-
EDTA containing 5 g porcine trypsin and 2 g ethylenediaminetetraacetic
acid (Trypsin) and neutral buffered formalin (NBF) were purchased
from Sigma-Aldrich and used as received. Fetal bovine serum (FCS)
was purchased from BioSera and used as received. All tissue culture
plates and ﬂasks were purchased from Greiner, except black 96 well
plates which were purchased from Costar. Poly (ethylene glycol) meth-
yl ether methacrylate (Mn= 300 gmol−1) (98%) (OEGMA), 2-cyano-2-
propyl benzodithioate (97%) (CPBD) and 2.2′-azobis(2-
methylpropionitrile) (98%) (AIBN)were purchased from Sigma-Aldrich
and used as received. Mono methacryloxypropyl poly(dimethylsilox-
ane)methacrylate (molecular weight 985 and 4600 gmol−1; PDMSMA9
and PDMSMA57 respectively) and methacryloxypropyl poly(dimethyl-
siloxane) dimethacrylate (molecular weight 1275 and 4460 gmol−1;
PDMSDMA12 and PDMSDMA55 respectively) were purchased from
Gelest and used as received.
2.2. Characterization
NMR spectra were recorded using a Bruker DPX-400 spectrometer
operating at 400 MHz for 1H NMR. UV–vis spectra were collected
using a Thermo Fisher NanonDrop 2000c spectrophotometer with a
quartz cuvette. Data was analyzed using the NanoDrop2000 software.
ProSafe + scintillation cocktail (Meridian Biotechnologies Ltd.) was
used as received. All radiation measurements were carried out using a
liquid scintillation counter (Packard Tri-carb 3100TR; Isotech). Triple
detection GPC was performed to measure molecular weights and mo-
lecular weight distributions using a Malvern Viscotek instrument. The
instrument was equipped with a GPCmax VE2001 autosampler, two
Viscotek T6000 columns (and a guard column), a refractive index (RI)
detector VE3580 and a 270 Dual Detector (light scattering and viscom-
eter) with amobile phase of THF containing 2 v/v% of trimethylamine at
35 °C with a ﬂow rate of 1 mLmin−1. A Nikon Eclipse Ti-E inverted mi-
croscope system was used to collect cell images. Statistical analyses
were carried out on SPSS Statistics V22 software; oneway test of homo-
geneity of variances and ANOVA as well as Dunnett's T3 post-hoc eval-
uation were conducted, p b 0.05 was regarded to be statistically
signiﬁcant.
2.3. Synthesis of polymers
All RAFT polymerizationswere conducted at a constant ratio of chain
transfer agent to initiator of [CPBD]:[AIBN] = 1:0.2.
For the synthesis of p(OEGMA), targeting DPn = 60 monomer units,
AIBN (2.7 mg, 0.016 mmol), CPBD (18.4 mg, 0.083 mmol) and OEGMA
(1.5 g, 5 mmol) were added to a 25 mL Schlenk tube equipped with a
magnetic stirrer bar. t-BuOH (4.5 mL, 30 wt% wrt. monomer, deoxygen-
ated via N2 purge) was added and the resulting solution degassed by
ﬁve cycles of freeze/pump/thaw. After the ﬁnal thaw cycle, the ﬂask
was backﬁlled with N2. The reaction ﬂask was placed into a pre-heated
oil bath (70 °C) and stirred for 8 h, afterwhich the reactionmediumwas
observed to be slightly turbid. The polymerization was stopped by
cooling the ﬂask to ambient temperature, exposing its contents to air
and diluting the reaction medium with t-BuOH. The solution was con-
centrated by rotary evaporation and precipitated into cold petroleum-
ether (40–60) to give a pink liquid. The samplewas dried under vacuum
at 40 °C for 24 h and analyzed by 1H NMR in CDCl3 and GPC with a mo-
bile phase of THF.
In a typical synthesis of p(OEGMA-stat-PDMSMA9), targeting DPn=
60 monomer units (OEGMA/PDMSMA9 50/50), AIBN (2.7 mg,
0.016 mmol), CPBD (18.4 mg, 0.083 mmol), OEGMA (0.148 g,
0.492 mmol) and PDMSMA9 (Mn = 985 gmol−1, 1.5 g, 1.524 mmol)
were added to a 25 mL Schlenk tube equipped with a magnetic stirrerbar. t-BuOH (4.96 mL, 30 wt% wrt. monomer, deoxygenated via N2
purge) was added and the resulting solution degassed by ﬁve cycles of
freeze/pump/thaw. After the ﬁnal thaw cycle, the ﬂask was backﬁlled
with N2. The reaction ﬂask was placed into a pre-heated oil bath
(70 °C) and stirred for 24 h, after which the reaction medium was ob-
served to be slightly turbid. The polymerization was stopped by cooling
the ﬂask to ambient temperature, exposing its contents to air and dilut-
ing the reactionmediumwith t-BuOH. The solutionwas concentrated by
rotary evaporation and precipitated into cold MeOH to give a pink liq-
uid. The sample was dried under vacuum at 40 °C for 24 h and analyzed
by 1H NMR in CDCl3 and GPC with a mobile phase of THF.
In a typical branched polymerization synthesis of p(OEGMA-stat-
PDMSMA9-stat-PDMSDMA12), targeting DPn = 60 monomer units
(OEGMA/PDMSMA9 50/50), AIBN (5.6 mg, 0.034 mmol), CPBD
(37.5 mg, 0.169 mmol), OEGMA (1.524 g, 5 mmol), PDMSMA9 (Mn =
985 gmol−1, 5 g, 5 mmol) and PDMSDMA12 (Mn = 1275 gmol−1,
0.205 g, 0.158 mmol) were added to a 100 mL Schlenk tube equipped
with amagnetic stirrer bar. t-BuOH (20.3mL, 30wt%wrt. monomer, de-
oxygenated via N2 purge) was added and the resulting solution
degassed by ﬁve cycles of freeze/pump/thaw. After the ﬁnal thaw
cycle, the ﬂask was backﬁlled with N2. The reaction ﬂask was placed
into a pre-heated oil bath (70 °C) and stirred for 24 h, after which the
reactionmediumwas observed to be slightly turbid. The polymerization
was stopped by cooling the ﬂask to ambient temperature, exposing its
contents to air and diluting the reactionmediumwith t-BuOH. The solu-
tion was concentrated by rotary evaporation and precipitated into
MeOH to give a pink liquid. The sample was dried under vacuum at
40 °C for 24 h and analyzed by 1H NMR spectroscopy in CDCl3 and
GPC with a mobile phase of THF.
CTA removal involved a ratio of polymer:AIBN = 1:20. In a typical
CTA removal p(PDMS(9)48-stat-OEGMA12) (5.3811 g, 0.112 mmol) was
dissolved in toluene (73 mL, deoxygenated via Ar purge) in a 100 mL
schlenk ﬂask equipped with a stirrer bar. AIBN (369 mg, 2.24 mmol)
was added to the reaction ﬂask and purged with Ar. The temperature
was raised to 80 °C for 2.5 h. After the reaction with AIBN, the polymer
was precipitated in cold MeOH and a white liquid was isolated by
decanting the MeOH. The product was dried in vacuo then analyzed
by 1H NMR spectroscopy in CDCl3.
2.4. Solubilization/miscibility studies of polymers in silicone oils
In a typical solubilization experiment, polymer (1 mL) and silicone
oil (SiO1000; 1 mL) were syringed into a glass vial to create a 50 v/v%
mixture and placed on a roller for 3 days. The solutionswere diluted sys-
tematically by adding silicone oil to decrease the amount of polymer by
10 v/v%, rolled for 3 days each time, until a soluble/miscible concentra-
tion was reached (i.e. 40, 30, 20, 10 also 5 and 1 v/v% were tested).
2.5. Radiometric studies and analysis of drug solubility in silicone oils and
release
To determine solubility of drugs in silicone oil, saturated solutions of
atRA and Ibu in silicone oil (SiO1000) were prepared by mixing atRA
(11.6 mg) or Ibu (32 mg) with tritiated versions of the drug (10 μCi)
in EtOH (2 mL); after evaporation of the solvent at ambient tempera-
ture, SiO1000 (5 mL) was added to the residual solid and the solution
was stirred for 2 weeks. The sample was ﬁltered using a syringe pump
(4 mL/h) and 0.45 μm PTFE ﬁlters. Samples of the ﬁltered oils (20 μL)
were then solubilised in diethyl ether (8mL) before scintillation cocktail
(10 mL) was added. Radiation was then measured on a scintillation
counter and saturation concentrations were determined.
Amounts of drug added to the samples were altered depending on
targeted ﬁnal concentrations. Solutions of 200 μg/mL: atRA (1 mg) and
tritiated atRA (6 μCi) weremixed in EtOH (2mL) and the same protocol
was followed. Solutions of 20 μg/mL: atRA (0.1 mg) and tritiated atRA
(2 μCi) weremixed in EtOH (2mL) and the same procedure was carried
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mixed in EtOH (2 mL) and the same protocol was followed.
For the preparation of both atRA and Ibu solutions in
p(PDMSMA(9)48-stat-OEGMA12) blends, 5 and 10 v/v% content of poly-
mer blends were prepared by mixing for 3 days and loaded with drug
by following the same protocols as described above.
To determine release concentrations of drug, 1 mL of silicone oil or
p(PDMSMA(9)48-stat-OEGMA12) blend (5 or 10 v/v%) with determined
concentration of drug was placed in a 24 well plate over 0.5 mL media
(containing 1% Pen-Strep, 1% Amphotericin B and supplemented with
10% FCS). Samples of media (0.5 mL) were taken and replaced at deter-
mined time intervals; daily for the ﬁrst critical week then every 2–
3 days for the remainder of the study, using a 1 mL syringe and 25
gauge needle for up to 71 days. Sampling and withdrawing of the
media was done very carefully in order to avoid any emulsiﬁcation of
the oil. Media (250 μL) was mixed with scintillation cocktail (10 mL)
and analyzed by liquid scintillation counting.
2.6. Cytotoxicity assays of drug compounds and polymers
Cells were cultured at 37 °C in a dark, humid 5% CO2 incubator in
media containing 1% Pen-Strep, 1% Amphotericin B and supplemented
with 10% FCS. For these studies, cells were used between passages 22
and 25. Multiple assays were carried out on ARPE-19 cells to study the
effects of different drug concentrations on cell viability, metabolic activ-
ity and cell morphology. 18,000 cells/well were seeded in a 48 well tis-
sue culture plate and left for 1 or 7 days to adhere to the plate. The 7 day
sampleswere fed oncewithin theweek by replacing 450 μL oldmedium
with 500 μL fresh culturemedium. After the predetermined timeperiod,
the media was aspirated from all wells and replaced with 0.6 mL fresh
media containing polymer blends or controls. Controls included:
media, SiO1000 (0.2 mL) and a positive control (20 v/v% DMSO in
water). Cells were incubated for 1 to 7 days before the following assays
could be performed.
Resazurinwas dissolved in PBS at 0.1mg/mL, ﬁltered tomake a ster-
ile stock solution and stored at 4 °C in the dark. Medium was removed
and replaced with resazurin solution (10 μL stock solution per 100 μL
medium). Plates were incubated in the dark at 37 °C for 4 h. Media
was removed and put in black 96-well plastic plates; resoruﬁn ﬂuores-
cencewas readusinga FluostarOptimaspectroﬂuorometer (λExcitation=
530 nm; λEmission = 590 nm). All values were normalised to negative
control wells on each plate. Finally statistical analysis was performed.
Following removal of resazurin solution, cells were washed with PBS
(500 μL) then ﬁxed for 10 min in 10% neutral buffered formalin (NBF;
10% formalin, approximately 4% formaldehyde). NBF was discarded and
the cells washed again with PBS. A phalloidin solution was used to stain
the F-actin of the cytoskeleton of the cell. A phalloidin solution was pro-
duced at 1 mg powder in 1.5 mL MeOH according to manufacturer's in-
struction. The solution was then diluted 1 in 100 (in fresh PBS) and 75 μL
was placed in eachwell followed by 30min of incubation at 4 °C. Phalloidin
solution was removed and the cells washed with PBS.
DAPI was used to stain the nuclei of the cell. A stock solution of DAPI
wasmade at 1:1000with PBS, then further diluted to aworking solution
of 1:10 PBS, 75 μL was placed in each well and incubated for 10 min at
4 °C. Cells were washed with PBS and placed under 500 μL PBS. Cells
were then imaged using ﬂuorescence microscopy.
3. Results and discussion
3.1. Drug selection and design of silicone oil-soluble/miscible polymers with
potential hydrogen-bonding capability
The use of hydrogen bonding to promote and direct self-assembly in
supramolecular systems has been reported for many years [28]; exam-
ples include imide-amine [29], amide-amide [30,31], amide-amine [32]
and thioamide-thioamide [33] althoughmany other systems have beendescribed. One complementary donor-donor-acceptor-acceptor multi-
ple-hydrogen bonded system, the ureido-pyrimidinone, has been stud-
ied in detail since reports of dimerisationwere highlighted in non-polar
solvents [34]. The introduction of ethylene glycol spacer units within
networks of multifunctional ureido-pyrimidones was shown to reduce
association within non-polar solvents with a strong correlation to
chain length of the incorporated poly(ethylene glycol), (PEG) [35]. De-
spite this, the use of pH-dependent acid-ether hydrogen-bonding inter-
actions has been reported in the context of controlled colloidal
association [36] and emulsion-engineering [37,38] in aqueous environ-
ments. The potential for acid-ether hydrogen bonding within a silicone
oil environment, therefore, presented an opportunity to moderate the
release of acid functional drugs from the tamponade. Two drug classes
that have been repeatedly highlighted within recent reviews and re-
ports of ocular research were of interest to this study, namely anti-in-
ﬂammatory [18,39] and anti-proliferative [40] compounds. The
targeted hydrogen bonding interaction was potentially ideal for two
speciﬁc acid-functional drugs, ibuprofen (Ibu) and all-trans retinoic
acid (atRA), as both drugs have been shown in animalmodels to provide
beneﬁcial effects in ocular conditions requiring inﬂammation and pro-
liferation control respectively [41–45].
The introduction of PEG to silicone oil presents challenges as the
water-soluble polymer is practically insoluble within the non-polar sil-
icone oil environment. A series of copolymer structures were designed
to overcome this issue and synthesized using the controlled radical po-
lymerization technique reversible addition-fragmentation chain trans-
fer polymerization (RAFT; Scheme 1A) using azobisisobutyronitrile
(AIBN) as the free radical initiator. Linear statistical copolymers of the
macromonomers oligo(ethyleneglycol) monomethyl ether methacry-
late (DPn = 4 monomer units; OEGMA) and two chain lengths of
mono methacryloxypropyl poly(dimethylsiloxane) methacrylate
(DPn = 9 or 57 monomer units; PDMSMA(x)) were targeted with an
overall number average degree of polymerization (DPn)=60monomer
unitswithin themain chain (Scheme1B). This DPn valuewas selected as
itwas judged to offer a large enough chain length to accommodate a sig-
niﬁcant number of OEGMA and PDMSMA side chains whilst not devel-
oping considerable increases in viscosity after addition to silicone oil.
A short OEGMA chainwas selected in order to present only a subtle change
in the solubility/miscibility of the poly(PDMSMA) linear polymers, and the
introduction of either 12 (Scheme 1Bi&ii) or 30 (Scheme 1Biii&iv) units of
OEGMA, with both PDMSMA macromonomers, was targeted within the
overall DPn=60 linear statistical copolymer; this allowed the impact of co-
polymer composition to be examined within the study.
In addition, a series of branched vinyl polymerswere designed to deter-
mine anybeneﬁts fromcomplexpolymer architectureswhenblendedwith
silicone oil. In our previouswork, andwork by others, the copolymerisation
of a multifunctional vinyl brancher at very low concentration within con-
trolled radical polymerizations has been shown to lead to fully solublema-
terials with very high molecular weights and comprising multiple primary
linear chains [46–54]. The linear chains are not tethered at either of the
chain ends, therefore, in any mass of polymer the number of chain ends
and the DPn of the component polymer chains is identical to a correspond-
ing sample of linear polymer prepared in the absence of brancher (Fig. 2);
the polymers designed here uniquely utilize a long methacryloxypropyl
poly(dimethylsiloxane) dimethacrylate (PDMSDMA(y)) branching mole-
cule with varying chain lengths, rather than the often reported small mol-
ecule divinyl branchers such as divinyl benzene or ethyleneglycol
dimethacrylate.
3.2. Synthesis and characterization of copolymers containing mono
methacryloxypropyl poly(dimethylsiloxane) methacrylate and
oligo(ethyleneglycol) monomethyl ether methacrylate and their miscibility
in silicone oil (SiO1000)
The RAFT synthesis of p(OEGMA60) in t-BuOH at 70 °C utilized 2-
cyano-2-propyl benzodithioate (CPBD) as the chain transfer agent and
Scheme 1. Synthesis of linear statistical graft copolymers of monomethacryloxypropyl poly(dimethylsiloxane) methacrylate and oligo(ethylene glycol) monomethyl ether methacrylate
used during this study. A) Reversible addition-fragmentation chain transfer synthesis; B) Schematic representation of structural and compositional variation within the statistical graft
copolymers i) low incorporation of hydrophilic grafts or similar chain length to hydrophobic chains; ii) variation of hydrophobic graft length; iii) increased composition of hydrophilic
chains, and iv) increased hydrophobic graft chain length at higher ratios of hydrophilic chains.
45H. Cauldbeck et al. / Journal of Controlled Release 244 (2016) 41–51was relatively straightforward, achieving N90% conversion of monomer
to polymer, accurately targeting the required DPn and maintaining low
dispersity (Table 1). Similarly, the synthesis of p(PDMSMA(x)60) homo-
polymerswas also straightforward but requiredmore stringent removal
of oxygen from the reaction solution prior to initiation due to itswell re-
ported solubility within silicone oils [55]. Polymers with low Ð valuesFig. 2. Schematic representation of polymers andmonomers used during the study: A) statistica
and oligo(ethylene glycol) monomethyl ether methacrylate (Cii); B) branched statistical graft c
(Ciii).and good targeting of molecular weight were achieved when using
the relatively short chain length macromonomer (x = 9 repeat units);
when the chain length of PDMSMA was increased to DPn = 57 units,
homopolymerization was signiﬁcantly less successful, achieving only
38% conversion under the same conditions as the previous homopoly-
mer (Table 1). This larger side chain DPn macromonomer generatedl graft copolymer ofmonomethacryloxypropyl poly(dimethylsiloxane)methacrylate (Ci)
opolymer synthesized using methacryloxypropyl poly(dimethylsiloxane) dimethacrylate
46 H. Cauldbeck et al. / Journal of Controlled Release 244 (2016) 41–51polymers with very high molecular weight and low Ð values despite
reaching very low conversion, suggesting a retardation of chain growth,
presumably through the increased steric hindrance from the long
PDSMA(57) chains.
Statistical copolymerization of OEGMA and PDMSMA(x) at a 1:4 or
1:1 M ratio respectively was successful in generating the required am-
phiphilic copolymers. The introduction of the short OEGMA monomer
was unable to signiﬁcantly enhance the conversion of the longer
PDMSMA(57)macromonomer even at a 1:1M ratio; however, the statis-
tical copolymers p(PDMSMA(9)48-stat-OEGMA12), p(PDMSMA(9)30-stat-
OEGMA30), p(PDMSMA(57)48-stat-OEGMA12) and p(PDMSMA(57)30-
stat-OEGMA30) were all recovered with low Ð values (1.08–1.21) and
molecular weights ranging from Mn = 33.300–350,600 g/mol. When
employing PDMSMA(9) both monomers appeared to be incorporated
into the polymers well, however, the polymers derived from
PDMSMA(57) were richer in OEGMA than targeted.
The introduction of branching within the various p(PDMSMA(9)n-
stat-OEGMAm) statistical copolymers was achieved by incorporation of
very low concentrations of PDMSDMA(y) (y=DPn=12 or 55monomer
units); targeting less than one dimethacrylate brancher per primary
chain on average (Fig. 2) to prevent crosslinking. The amount of
branching that resulted from the introduction of PDMSDMA(12) at a
CTA:brancher molar ratio of 1:0.95 was limited and the resulting poly-
mers maintained Mn values that were similar to the analogous linear
polymers synthesized in the absence of brancher; Ð values increased
as expectedwith concomitant increases inMw. The lack of successwith-
in the branching syntheses was presumed to be due to the length of the
chosen PDMSDMA(12) brancher being less than double the length of the
short PDMSMA(9), hence the interchain steric hindrance generated by
side chain overlap would prevent efﬁcient branching between growing
chains.
Increasing the chain length of the PDMSDMA(y) brancher from 12 to
55 monomer units was expected to overcome the problem of inter-
chain branching and, indeed, soluble polymers of considerably in-
creased molecular weights were prepared. As with previous reports of
branched vinyl polymers using multi-functional branchers, the statisti-
cal terpolymer p(PDMSMA(9)48-stat-OEGMA12-stat-PDMSDMA(55)0.95)
can be considered as having a large number of conjoined primary chains
that have been shown to be near-identical to polymers synthesized in
the absence of brancher. Through simple comparison of the Mn and
Mw values of the branched and un-branched polymers, it can be seen
that this polymer has an estimated number average of 9 conjoined
chains and an estimated weight average of 68 conjoined statisticalTable 1
Characterization of the synthesized study copolymers.
Target polymer composition Brancher
GPCa (THF
Mn
(g/mol)
p(OEGMA60) – 24,800
p(PDMSMA(9)60) – 51,200
p(PDMSMA(57)60) – 376,000
p(PDMSMA(9)48-stat-OEGMA12) – 47,650
p(PDMSMA(9)30-stat-OEGMA30) – 33,300
p(PDMSMA(57)48-stat-OEGMA12) – 350,600
p(PDMSMA(57)30-stat-OEGMA30) – 220,250
p(PDMSMA(9)48-stat-OEGMA12) PDMS-DMA(12)0.95 56,200
p(PDMSMA(9)30-stat-OEGMA30) PDMS-DMA(12)0.95 50,700
p(PDMSMA(9)48-stat-OEGMA12) PDMS-DMA(55)0.95 423,900
p(PDMSMA(9)30-stat-OEGMA30) PDMS-DMA(55)0.95 142,100
p(PDMSMA(9)24-stat-PDMSMA(57)24-stat-OEGMA12) – 149,700
p(PDMSMA(9)15-stat-PDMSMA(57)15-stat-OEGMA30) – 95,400
p(PDMSMA(9)24-stat-PDMSMA(57)24-stat-OEGMA12) PDMS-DMA(55)0.95 174,100
p(PDMSMA(9)15-stat-PDMSMA(57)15-stat-OEGMA30) PDMS-DMA(55)0.95 235,600
a GPC values (Mn, Mw and Đ) were determined using THF eluent at 1 mL min−1 ﬂow rate.
b 1H NMR measurements conducted in CDCl3 solvent and relative conversion calculated usi
(δ= 3.30 ppm). See Electronic Supporting Information, (ESI) Fig. S1 for an example of converprimary chains. The relevance of the weight average number of chains
lies in the recognition that the Mw value approximately represents the
molecular weight of the polymer chains at the mid-point of the weight
fraction or, in other words, approximately half of the physical mass of
the polymer sample is composed of structures with N68 conjoined
chains. Similar evaluation of the statistical terpolymer
p(PDMSMA(9)30-stat-OEGMA30-stat-PDMSDMA(55)0.95) shows a mate-
rialwith considerablymore branching (number average number of con-
joined primary chains = 4; weight average number of conjoined
primary chains=142), again indicating that steric factors are important
within the statistical copolymerization and branched
terpolymerizations. These estimations do rely on attaining similar con-
versions of both monomers in the presence and absence of brancher,
and the primary chains comprising the branched p(PDMSMA(9)30-stat-
OEGMA30-stat-PDMSDMA(55)0.95) terpolymer may have a slightly
higher PDMSMA(9) content, and therefore higher DPn, Mn and Mw
than the linear statistical copolymer analogue.
Comparisons of the size exclusion chromatograms clearly showed
an overlap of the refractive index (RI) and right angle light scattering
(RALS) signals for the linear statistical graft copolymers and branched
statistical graft terpolymers utilizing the shorter PDMSDMA(12)
brancher with only slight broadening of the distribution. This is in
stark contrast to the comparison of materials synthesized using the
PDMSDMA(55) brancher, where a signiﬁcant broadening was seen
using the RI detector and scattering was dominated by the high molec-
ular weight branched material within the RALS signal (see Electronic
Supporting Information (ESI), Fig. S2 and S3). To improve the potential
for successful branching and increase the amount of PDMS within the
polymers, the PDMS monomethacrylate portions of the linear and
branched graft copolymers were mixed to allow both long
(PDMSMA(57)) and short (PDMSMA(9)) chains to react into a statistical
linear terpolymer. The incorporation of OEGMA was not affected by
the additional monomer, however, the overall total molar conversion
of PDMSMA(x)was reducedwhen compared to the linear copolymer an-
alogues (Table 1). When used in branching reactions which utilized
only the PDMSDMA(55) brancher, the mixed monomer approach did
not considerably enhance the formation of branched polymer structures
(Fig. S4), probably due to the steric effects seen with shorter
brancher:monomer combinations and the inability of PDMSDMA(55)
to bridge between chains containing PDMSMA(57) side chains.
The miscibility/solubility of the copolymer structures with silicone
oil (SiO1000, viscosity = 900–1200 cSt) was evaluated qualitatively
through blending of the silicone oil with increasing amounts of each) 1H NMRb
Mw
(g/mol) Ð Polymer composition
Conversion(%)
PDMS OEGMA
30,400 1.23 p(OEGMA55) – 92
59,400 1.16 p(PDMSMA(9)58) 96 –
439,900 1.17 p(PDMSMA(57)23) 38 –
52,700 1.11 p(PDMSMA(9)47-stat-OEGMA11) 98 94
36,800 1.11 p(PDMSMA(9)24-stat-OEGMA29) 80 96
380,200 1.08 p(PDMSMA(57)22-stat-OEGMA9) 45 77
266,850 1.21 p(PDMSMA(57)14-stat-OEGMA20) 47 65
74,200 1.32 – 94 98
75,600 1.49 – 91 97
3,590,000 8.47 – 91 98
5,220,000 36.73 – 90 97
199,300 1.33 p(PDMSMA(9.57)37-stat-OEGMA11) 78 92
108,600 1.14 p(PDMSMA(9.57)23-stat-OEGMA29) 77 95
389,900 2.24 – 92 89
323,200 1.37 – 79 91
ng the peak area ratios of PDMS repeat units (δ= 3.80 ppm) and OEGMA repeat units
sion determination.
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p(OEGMA60), p(PDMSMA(9)60) and p(PDMSMA(57)60) were ﬁrst evalu-
ated and showed almost no solubility of p(OEGMA60), as expected,
and complete miscibility for both the p(PDMSMA(x)60) homopolymers
(Table 2).WhenOEGMAand PDMSMAwere statistically copolymerised
to incorporate just 12 units of OEGMA within the target DP60 polymer
chain, and utilizing PDMSMA(9) to form p(PDMSMA(9)48-stat-
OEGMA12), the resulting polymer was only miscible at b30 v/v%. A fur-
ther reduction in miscibility was seen when p(PDMSMA(9)30-stat-
OEGMA30) was tested, demonstrating the clearly negative effect of
OEGMA on the miscibility of these materials. Increasing the PDMSMA
graft lengthwithin the same target DP60 polymers, and nominal compo-
sitions, allowed the polymers p(PDMSMA(57)48-stat-OEGMA12) and
p(PDMSMA(57)30-stat-OEGMA30) to overcome the impact of OEGMA in-
corporation, even when OEGMA comprised 50 mol% of the target poly-
mer backbone repeat units. Due to the poor branching observed when
using PDMSDMA(12), terpolymers synthesized using this brancher
were not studied; however, very high molecular weight branched sta-
tistical terpolymers formed using PDMSDMA(55) exhibited improved
miscibilitywhen compared to their linear copolymer analogues, despite
only very small modiﬁcations of the overall nominal molar ratio of eth-
ylene glycol:dimethyl siloxane unitswithin these samples. The substitu-
tion of half of the PDMSDMA(9) with PDMSDMA(57), leading to the
synthesis of statistical terpolymers p(PDMSMA(9)24-stat-
PDMSMA(57)24-stat-OEGMA12) and p(PDMSMA(9)15-stat-
PDMSMA(57)15-stat-OEGMA30), resulted in a large impact on miscibility
as expected. It is interesting to note that within the linear copolymer
and terpolymer samples, high miscibility was only achievable when
PDMSMA(57) was present with a concomitant large decrease in the
molar content of ethylene glycol repeat units in the targeted polymers
to approximately ≤10 mol% (Table 2). The introduction of less than
one PDMSDMA(55) brancher per primary chain, therefore, allowed a
considerable increase in the molar content of ethylene glycol that
could be incorporated into the silicone oil/polymer mixture, potentially
due to the formation ofmicelle-like nanostructures; thiswas not further
investigated within this study.
To establish the beneﬁts of the silicone oil/graft statistical copolymer
mixtures in tamponade drug reservoir applications, the residual poly-
mer colour resulting from RAFT polymerization was ﬁrst removed by
cleavage of the remaining dithioester chain end groups. A single poly-
mer was selected for this modiﬁcation and subsequent drug release
studies, namely p(PDMSMA(9)48-stat-OEGMA12). Polymer selection
criteria included ease/lack of complexity of synthesis, miscibility with
silicone oil and the relatively low ethylene glycol content within the
ﬁnal polymer; high levels of p(OEGMA) may allow the incorporation
of signiﬁcant water levels within the silicone oil tamponade and this is
known to lead to a decrease of optical clarity over time through emul-
sion formation. Removal of the residual chain transfer agentwas accom-
plished by using a previously reported approach [56] involvingTable 2
Results of statistical graft homopolymer, copolymer and terpolymer/silicone oil miscibility stud
Target Polymer Brancher
Composition
p(OEGMA60) –
p(PDMSMA(9)60) –
p(PDMSMA(57)60) –
p(PDMSMA(9)48-stat-OEGMA12) –
p(PDMSMA(9)30-stat-OEGMA30) –
p(PDMSMA(57)48-stat-OEGMA12) –
p(PDMSMA(57)30-stat-OEGMA30) –
p(PDMSMA(9)48-stat-OEGMA12) PDMSDMA(55)
p(PDMSMA(9)30-stat-OEGMA30) PDMSDMA(55)
p(PDMSMA(9)24-stat-PDMSMA(57)24-stat-OEGMA12) –
p(PDMSMA(9)15-stat-PDMSMA(57)15-stat-OEGMA30) –treatment with AIBN in toluene at 80 °C for 2.5 h, after which a
colourlessmaterial (Scheme S1)was recovered and analyzed to conﬁrm
no change in molecular weight had occurred and the chain end func-
tionality had been completely removed (Fig. S5).
3.3. Cytotoxicty of p(PDMSMA(9)48-stat-OEGMA12) with ARPE-19 cells
The metabolic activity and morphology of ARPE-19 cells, a human
retinal pigment epithelial cell line [57], was studied as they contain
the same functional and structural properties of cell in vivo. Both pre-
and post-conﬂuent cells (1 day and 7 day growth respectively) were ex-
posed to silicone oil (SiO1000) and blends of p(PDMSMA(9)48-stat-
OEGMA12) with silicone oil at 10 v/v% for 1 and 7 days; a resazurin
assay was conducted, followed by phalloidin staining of the cells from
the assay. The resazurin assay contained negative (healthy cells) and
positive controls (cells exposed to 20% DMSO) as well as media with
no resazurin present to determine background signals. The controls
conﬁrmed the validity of the assay (Fig. 3), as therewas a signiﬁcant dif-
ference (p ≤ 0.05) between the negative control and the positive control,
however, no signiﬁcant difference (p ≤ 0.05) was observed between the
positive control and cells exposed to silicone oil or p(PDMSMA(9)48-stat-
OEGMA12) blends at 10 v/v% in silicone oil, indicating that the oil and
blends have no measurable effect on the metabolic activity of the
ARPE-19 cells.
Phalloidin and DAPI staining conﬁrmed the presence of attached
cells that were well-spread with typical actin stress ﬁber structures
when exposed to the oil and polymer blend. Images of phalloidin-
stained cells exposed to silicone oil, and the 10 v/v% blends alongside
negative control (healthy cells) for the two extreme time points exam-
ined (Fig. 4), and measurement of metabolic activity indicate that the
oils and polymer blend are non-cytotoxic to this cell type.
3.4. Controlling in vitro release of ibuprofen and all-trans retinoic acid from
tamponade blends containing silicone oil and p(PDMSMA(9)48-stat-
OEGMA12)
As discussed above, blends of silicone oil and p(PDMSMA(9)48-stat-
OEGMA12) were targeted to regulate the long term release of acid-func-
tional drugs due to the potential for hydrogen bonding with the ethyl-
ene glycol repeat units solubilised within the non-polar environment
of the silicone oil (Fig. 5). The measurement of drug release from sili-
cone oil has been previously described using various methods such as
studying depletion from the oil phase and employing a range of extrac-
tion techniques with organic solvents to allow subsequent UV–visible
spectroscopy to quantify concentrations, often via high pressure liquid
chromatography [58].
These techniques have considerable scope for inaccuracy and have
limited value when measuring release into cell culture media; direct
measurement of atRA and Ibu in culture media is hampered by anies and target mole% of PDMS and ethylene glycol repeat units.
Target composition
(mol% of total monomer) Miscibility in Silicone Oil
EG DMS (% v/v)
100 0 b1
0 100 Miscible
0 100 Miscible
10 90 b30
30.8 69.2 b5
1.7 98.3 Miscible
6.5 93.5 Miscible
9 91 b40
27 73 b40
2.9 97.1 Miscible
10.8 89.2 Miscible
Fig. 3. Resazurin assaywith appropriate controls to determine the cytotoxicity of silicone oil (SiO1000) and blends of p(PDMSMA(9)48-stat-OEGMA12) with silicone oil (SiO1000) at 10 v/v%.
Pre- and post-conﬂuent ARPE-19 cells (grown for 1 and 7 days respectively)were exposed to the oils for 1 and 7 d. A: Pre-conﬂuent cells exposed for 1 day, B: Post-conﬂuent cells exposed
for 7 days, C: Pre-conﬂuent cells exposed for 7 days andD: Post-conﬂuent cells exposed for 1 day. (mean, error bars represent±1 standard deviation); n=3. *, Signiﬁcance byANOVA and
Dunnett's T3 post-hoc evaluation (p ≤ 0.05).
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such as fetal calf serum (Fig. S7). Our attempts to accurately quantify
the concentration of drugs in silicone oil directly by 1H nuclearmagnetic
resonance spectroscopy of the oil were also impeded by their reported
low solubility in this liquid. To overcome these issues, mixtures of
drug compounds with relatively low ratios of radiolabelled drugs (3H-
Ibu and 3H-atRA)were employed, allowing directmeasurement of sam-
ples containing very low drug concentrations without subsequentFig. 4. ARPE-19 cells stainedwith phalloidin (green, F-actin cytoskeleton) and DAPI (blue, nucle
to a 10 v/v% blend of p(PDMSMA(9)48-stat-OEGMA12) for 1 day; and post-conﬂuent cells: D)
p(PDMSMA(9)48-stat-OEGMA12) for 7 days. Scale bars represent 50 μm. Additional timescales smanipulation and additional error. Additionally, 3H-labelled drugs are
essentially unchanged chemically and the use of techniques to amplify
detection that require conjugation of ﬂuorophores are avoided.
Initial release studies into media were conducted using 3H-Ibu/Ibu
mixtures dissolved at a concentration of 1mg/mL (speciﬁc activity rang-
ing from 1.39–1.61 μCi/μg across different experiments) either in sili-
cone oil or a blend of silicone oil and p(PDMSMA(9)48-stat-OEGMA12)
at 5 or 10 v/v% addition of copolymer (Fig. 6A).i). Pre-conﬂuent cells: A)Negative control; B) Exposed to silicone oil (SiO1000); C) Exposed
Negative control; E), Exposed to silicone oil (SiO1000); F) Exposed to a 10 v/v% blend of
tudied; see Fig. S6.
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from silicone oil was initially very rapid with approximately 65% of
the dissolved drug released in the ﬁrst day of the experiment; complete
release of drug occurred after 3 days under the conditions described
above. The inclusion of 5 v/v% of p(PDMSMA(9)48-stat-OEGMA12) no-
ticeably reduced the rate of Ibu release, extending the release to be-
tween 6 and 7 days whilst the inclusion of 10 v/v% of the copolymer
slowed the release of Ibu to b50 wt% over the ﬁrst day and extending
the release for over 1 week. The additional reduction in release rate ob-
served at the higher inclusion rate of the copolymer suggests that a sig-
niﬁcant amount of Ibu remained unboundwithin the sample containing
5 v/v% statistical graft copolymer.
The experiment was repeated using 3H-atRA/atRA mixtures but due
to the reported low solubility of atRA in silicone oil [58], a concentration
of 20 μg/mL was employed. As seen with the Ibu release from silicone
oil, the absence of copolymer allowed a relatively fast release of drug
(N60%) within 3 days and 80% release was seen after 9 days (Fig. 6B).
Within a clinical setting, the release of atRA would ideally be sustained
over several months, thereforemonitoringwas conducted for extended
periods. The inclusion of 5 and 10 v/v% of p(PDMSMA(9)48-stat-
OEGMA12) led to the same effect observed for Ibu; that the addition of
the statistical graft copolymer retarded the release of the acid-function-
al drug. In this case, however, the difference between the two statistical
graft copolymer inclusion levels was very small over the 72 day sam-
pling period, with both systems reaching 80% release at approximately
40 days. This approximate 4-fold delay in release of atRAmay offer con-
siderable clinical beneﬁt, potentially enabling dosing from the silicone
oil tamponade drug reservoir to be maintained within therapeutic
limits. The concentration of the 3H-atRA/atRA mixture was increased
to 200 μg/mL and identical release studies were undertaken (Fig. 6C).
As observed at the lower atRA concentration, the absence of statistical
graft copolymer led to a rapid release over the ﬁrst 4 days (N60 wt%)
and the inclusion of 5 v/v% of p(PDMSMA(9)48-stat-OEGMA12) led to a
reduction in release rate. Interestingly, under these conditions, the addi-
tion of 10 v/v% of the statistical graft copolymer did lead to a further re-
tardation of release at this higher concentration of drug; with the three
conditions reaching nearly 100% release in approximately 50 days in the
absence of statistical graft copolymer, and 95% and 90% release after
72 days in the presence of 5 v/v% and 10 v/v% copolymer respectively.
This strongly suggests that the inclusion of 5 v/v% of p(PDMSMA(9)48-
stat-OEGMA12) within the silicone oil at a atRA concentration of 20 μg/
mL had resulted in the binding of almost all of the drug to the polymer
OEGMA sites and the addition of further OEGMA was unnecessary;
however, at higher atRA concentrations (200 μg/mL), the increased re-
tardation seen from a doubling of the copolymer addition would sug-
gest that the copolymer was predominantly saturated at an inclusionFig. 5. Schematic representation of silicone oil-aqueous media interface: A) drug molecu
methacryloxypropyl poly(dimethylsiloxane) methacrylate polydimethylsiloxane methacryla
the ethylene glycol repeat units leading to slow release of drug; B) drug dissolved solely wi
bonding between acid functional drugs and the ethylene glycol units within the statistical grafrate of 5 v/v%. Even under conditions where the polymer binding sites
are saturated, the difference in release rate with different copolymer in-
clusion is noticeable at the ﬁrst measurement (day 1) where the ab-
sence of copolymer at an atRA concentration of 20 μg/mL led to
approximately 35% release and the presence of copolymer at 5 v/v%
and 10 v/v% reduced the release to a measured 20% and 18% respective-
ly. At the higher atRA concentration of 200 μg/mL, the values after 1 day
were approximately 20%, 16% and 15% for the absence and inclusion of
copolymer at 5 v/v% and 10 v/v% respectively.
4. Conclusions
A vitrectomy and subsequent replacement of the vitreous humour
with a silicone oil tamponade is a critical tool in the clinical manage-
ment ofmany cases of retinal detachment and the opportunity to utilize
the tamponade as a drug delivery reservoir has been an elusive target
for many years. Low drug solubilities and poor control of drug release
are two key factors in the lack of clinical therapeutic tamponade op-
tions. The bespoke design of silicone oil-soluble polymer excipients to
enhance solubility and mediate drug release is an area with consider-
able options and one that appears to have been largely unstudied. To
the best of our knowledge, the use of PEG-containing silicone-oil solu-
ble/miscible polymers to control drug release in an ophthalmic setting
has not been reported previously, but the results herein suggest newav-
enues for this area of drug delivery research. The polymer chosen for de-
tailed study was selected based on its simplicity, both of synthesis and
architecture, and represents an optionwith clear translational potential.
By selecting to target acid-functional drug compounds, we have also
demonstrated the ability to enable anti-inﬂammatory drug release
over a 1 week period and the sustained release of an anti-proliferative
drug over several months. This may be important to counteract the im-
mediate effects of damage and prevent further injury during the recov-
ery stages. This strategy offers new approaches to enable clinicians in
their prevention of sight loss and to aid patients during their recovery
from retinal detachment.
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